Samsung Group's new bio-pharmaceutical Friday announced that it will spend $ 740 million to build a new plant in South Korea, after the completion of pharmaceutical production capacity can be doubled. The company is expected to be completed by 2018.
Samsung Biological Products Co., Ltd. was founded in 2011, 97 percent by Samsung Electronics Holdings, the new plant is completed, Samsung is expected to become the world's largest bio-pharmaceutical companies foundry. Currently, Samsung biological already operates a production plant, next year will build a second plant is five times as large former, and now plans to build a third annual capacity of 180,000 liters goals. New plant construction plan highlights the Samsung ambition Pharmaceutical Technology in.
Analysts said, as the slowdown in the smart phone business, Pharmaceutical Technology described under the Samsung Group has a business growth potential. Samsung said it wanted to succeed semiconductor manufacturing operations into the production of biological science and technology among.
没有评论:
发表评论